ipilimumab
Yervoy
Pharmaceutical company: Bristol-Myers Squibb
NEW INDICATION & DOSAGE
Unresectable or microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer in combination with nivolumab
Adults and children ages 12 and older weighing 40 kg or more: 1-mg/kg IV infusion immediately following nivolumab 240-mg IV infusion on the same day every 3 weeks for a maximum of 4 doses. After completion of combination therapy, continue nivolumab as a single agent per nivolumab manufacturer's instructions.
Children ages 12 and older weighing less than 40 kg: 1-mg/kg IV infusion immediately following nivolumab 3-mg/kg IV infusion on the same day every 3 weeks for a maximum of 4 doses. After completion of combination therapy, continue nivolumab as a single agent per nivolumab manufacturer's instructions.
Unresectable or metastatic hepatocellular cancer in combination with nivolumab
Adults: 3-mg/kg IV infusion immediately following nivolumab 1-mg/kg IV infusion on the same day every 3 weeks for a maximum of 4 doses. After completion of combination therapy, continue nivolumab as a single agent per nivolumab manufacturer's instructions.
Released: July 2025
Nursing Drug Handbook
© 2025 Wolters Kluwer N.V., its subsidiaries and/or its licensors. All rights reserved.
nivolumab
Opdivo
Pharmaceutical company: Bristol-Myers Squibb
NEW INDICATION & DOSAGE
Unresectable or microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer in combination with ipilimumab
Adults and children ages 12 and older weighing 40 kg or more: 240-mg IV infusion followed by ipilimumab 1-mg/kg IV infusion on the same day every 3 weeks for a maximum of 4 doses; then 240 mg every 2 weeks or 480 mg every 4 weeks as a single agent until disease progression, unacceptable toxicity occurs, or for up to 2 years.
Children ages 12 and older weighing less than 40 kg: 3-mg/kg IV infusion followed by ipilimumab 1-mg/kg IV infusion on the same day every 3 weeks for a maximum of 4 doses; then 3 mg/kg every 2 weeks or 6 mg/kg every 4 weeks as a single agent until disease progression, unacceptable toxicity occurs, or for up to 2 years.
Unresectable or metastatic hepatocellular cancer in combination with ipilimumab
Adults: 1-mg/kg IV infusion followed by ipilimumab 3-mg/kg IV infusion on the same day every 3 weeks for a maximum of 4 doses; then 240 mg every 2 weeks or 480 mg every 4 weeks as a single agent until disease progression, unacceptable toxicity occurs, or for up to 2 years.
Released: July 2025
Nursing Drug Handbook
© 2025 Wolters Kluwer N.V., its subsidiaries and/or its licensors. All rights reserved.
upadacitinib
Rinvoq
Pharmaceutical company: AbbVie
NEW INDICATION & DOSAGE
Giant cell arteritis
Adults: 15 mg PO daily in combination with a tapering course of corticosteroids. May continue as monotherapy after corticosteroids are stopped.
Released: July 2025
Nursing Drug Handbook
© 2025 Wolters Kluwer N.V., its subsidiaries and/or its licensors. All rights reserved.